Contemporary management of chronic obstructive pulmonary disease: scientific review.

CONTEXT The care of patients with chronic obstructive pulmonary disease (COPD) has changed radically over the past 2 decades, and novel therapies can not only improve the health status of patients with COPD but also modify its natural course. OBJECTIVE To systematically review the impact of long-acting bronchodilators, inhaled corticosteroids, nocturnal noninvasive mechanical ventilation, pulmonary rehabilitation, domiciliary oxygen therapy, and disease management programs on clinical outcomes in patients with COPD. DATA SOURCES MEDLINE and Cochrane databases were searched to identify all randomized controlled trials and systematic reviews from 1980 to May 2002 evaluating interventions in patients with COPD. We also hand searched bibliographies of relevant articles and contacted experts in the field. STUDY SELECTION AND DATA EXTRACTION We included randomized controlled trials that had follow-up of at least 3 months and contained data on at least 1 of these clinical outcomes: health-related quality of life, exacerbations associated with COPD, or death. For pulmonary rehabilitation, we included studies that had a follow-up of at least 6 weeks. Using standard meta-analytic techniques, the effects of interventions were compared with placebo or with usual care. In secondary analyses, the effects of interventions were compared against each other, where possible. DATA SYNTHESIS Long-acting beta2-agonists and anticholinergics (tiotropium) reduced exacerbation rates by approximately 20% to 25% (relative risk [RR] for long-acting beta2-agonists, 0.79; 95% CI, 0.69-0.90; RR for tiotropium, 0.74; 95% CI, 0.62-0.89) in patients with moderate to severe COPD. Inhaled corticosteroids also reduced exacerbation rates by a similar amount (RR, 0.76; 95% CI, 0.72-0.80). The beneficial effects were most pronounced in trials enrolling patients with FEV1 between 1 L and 2 L. Combining a long-acting beta2-agonist with an inhaled corticosteroid resulted in an approximate 30% (RR, 0.70; 95% CI, 0.62-0.78) reduction in exacerbations. Pulmonary rehabilitation improved the health status of patients with moderate to severe disease, but no material effect was observed on long-term survival or hospitalization rates. Domiciliary oxygen therapy improved survival by approximately 40% in patients with PaO2 lower than 60 mm Hg, but not in those without hypoxia at rest. The data on disease management programs were heterogeneous, but overall no effect was observed on survival or risk of hospitalization. Noninvasive mechanical ventilation was not associated with improved outcomes. CONCLUSIONS A significant body of evidence supports the use of long-acting bronchodilators and inhaled corticosteroids in reducing exacerbations in patients with moderate to severe COPD. Domiciliary oxygen therapy is the only intervention that has been demonstrated to prolong survival, but only in patients with resting hypoxia.

[1]  L. Stead,et al.  Self-help interventions for smoking cessation. , 2005, The Cochrane database of systematic reviews.

[2]  Pamela Tabar,et al.  Disease management. , 2005, Healthcare informatics : the business magazine for information and communication systems.

[3]  S. Small.  Review: long acting β2 agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease , 2004, Evidence-based nursing.

[4]  S. Rennard,et al.  Rescue! Therapy and the paradox of the Barcalounger , 2003, European Respiratory Journal.

[5]  Steven Piantadosi,et al.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.

[6]  G. Guyatt,et al.  Influence of lung volume reduction surgery (LVRS) on health related quality of life in patients with chronic obstructive pulmonary disease , 2003, Thorax.

[7]  T. Marrie,et al.  Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. , 2003, Archives of internal medicine.

[8]  John Mullooly,et al.  Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. , 2003, The New England journal of medicine.

[9]  K. Shirato,et al.  Correlation between change in pulmonary function and suppression of reactive nitrogen species production following steroid treatment in COPD , 2003, Thorax.

[10]  R. Chazan,et al.  The cellular composition and macrophage phenotype in induced sputum in smokers and ex-smokers with COPD. , 2003, Chest.

[11]  D. Sin,et al.  Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. , 2003, Circulation.

[12]  R. Kaplan,et al.  Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. , 2003, American journal of respiratory and critical care medicine.

[13]  Elizabeth M. Borycki,et al.  Reduction of Hospital Utilization in Patients With Chronic Obstructive Pulmonary Disease: A Disease-Specific Self-management Intervention , 2003 .

[14]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[15]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[16]  V. Brusasco,et al.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.

[17]  J. van der Palen,et al.  Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. , 2002, American journal of respiratory and critical care medicine.

[18]  T. Bengtsson,et al.  Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study , 2002, European Respiratory Journal.

[19]  Vic Hasselblad,et al.  Interventions used in disease management programmes for patients with chronic illnesswhich ones work? Meta-analysis of published reports , 2002, BMJ : British Medical Journal.

[20]  G. Marks,et al.  Primary care Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease , 2022 .

[21]  P. Jones,et al.  Oral theophylline for chronic obstructive pulmonary disease. , 2002, The Cochrane database of systematic reviews.

[22]  J. Yates,et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[23]  Clement J McDonald,et al.  Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. , 2002, JAMA.

[24]  C. Rand,et al.  Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. , 2002, Preventive medicine.

[25]  A. Corrado,et al.  The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients , 2002, European Respiratory Journal.

[26]  Arieh Eden,et al.  Patients at High Risk of Death After Lung-Volume-Reduction Surgery , 2002 .

[27]  N. Anthonisen,et al.  Hospitalizations and mortality in the Lung Health Study. , 2002, American journal of respiratory and critical care medicine.

[28]  P. Young,et al.  Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study , 2002, European Respiratory Journal.

[29]  H. Hoogsteden,et al.  Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness , 2002, Thorax.

[30]  E. Bateman,et al.  A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. , 2002, Chest.

[31]  P. Jeffery,et al.  The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. , 2002, American journal of respiratory and critical care medicine.

[32]  O. Johnell,et al.  Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler® , 2002, European Respiratory Journal.

[33]  R. Goldstein,et al.  The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. , 2002, Canadian respiratory journal.

[34]  M. Decramer,et al.  Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial , 2002, European Respiratory Journal.

[35]  G. Della Cioppa,et al.  Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. , 2002, Chest.

[36]  L. Goldman,et al.  beta-Blockers and reduction of cardiac events in noncardiac surgery: clinical applications. , 2002, JAMA.

[37]  Huong Q. Nguyen,et al.  Exercise training improves outcomes of a dyspnea self-management program. , 2002, Journal of cardiopulmonary rehabilitation.

[38]  P. Jones.  Interpreting thresholds for a clinically significant change in health status in asthma and COPD , 2002, European Respiratory Journal.

[39]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[40]  J. V. van Noord,et al.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium , 2002, European Respiratory Journal.

[41]  P. Barnes,et al.  Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids , 2002, European Respiratory Journal.

[42]  N. Anthonisen.  Inhaled steroids in chronic obstructive pulmonary disease. , 2002, Canadian respiratory journal.

[43]  P. Jones,et al.  Health status measurement in chronic obstructive pulmonary disease , 2001, Thorax.

[44]  R. Pauwels,et al.  Long-acting inhaled β2-agonist therapy in asthma , 2001 .

[45]  R. Dahl,et al.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[46]  D. Coultas,et al.  The health impact of undiagnosed airflow obstruction in a national sample of United States adults. , 2001, American journal of respiratory and critical care medicine.

[47]  S. Rennard,et al.  Alternative Mechanisms for Long-Acting β2-Adrenergic Agonists in COPD , 2001 .

[48]  L. Fregonese,et al.  Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression. , 2001, The European respiratory journal.

[49]  GunnarEngström,et al.  Occurrence and Prognostic Significance of Ventricular Arrhythmia Is Related to Pulmonary Function , 2001 .

[50]  B. Hedblad,et al.  Occurrence and Prognostic Significance of Ventricular Arrhythmia Is Related to Pulmonary Function: A Study From “Men Born in 1914,” Malmö, Sweden , 2001, Circulation.

[51]  J. Finnerty,et al.  The effectiveness of outpatient pulmonary rehabilitation in chronic lung disease: a randomized controlled trial. , 2001, Chest.

[52]  R. Zuwallack,et al.  Use of a Long-acting Inhaled β2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease , 2001 .

[53]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[54]  C. Murray,et al.  Burden of disease--implications for future research. , 2001, JAMA.

[55]  Christine Jenkins,et al.  GOLD SCIENTIFIC COMMITTEE. GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. NHLBI/WHO GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (COLD) WORKSHOP SUMMARY , 2001 .

[56]  P M Calverley,et al.  Health status deterioration in patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[57]  R. Zuwallack,et al.  Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[58]  D. Mant,et al.  Nicotine replacement therapy for smoking cessation. , 2004, The Cochrane database of systematic reviews.

[59]  S. Rennard,et al.  Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. , 2001, Chest.

[60]  R. Pauwels,et al.  Long-acting inhaled beta(2)-agonist therapy in asthma. , 2001, American journal of respiratory and critical care medicine.

[61]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[62]  H. Magnussen,et al.  Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. , 2000, Respiratory medicine.

[63]  B. Celli,et al.  Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. , 2000, Chest.

[64]  Dirkje S Postma,et al.  Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study , 2000, The Lancet.

[65]  M. Fiore.  US public health service clinical practice guideline: treating tobacco use and dependence. , 2000, Respiratory care.

[66]  J. Wedzicha,et al.  Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[67]  M. Decramer,et al.  Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. , 2000, The American journal of medicine.

[68]  D. Hansell,et al.  Effect of lung-volume-reduction surgery in patients with severe emphysema. , 2000, The New England journal of medicine.

[69]  T. Rubio,et al.  Results of a home-based training program for patients with COPD. , 2000, Chest.

[70]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[71]  W. Hop,et al.  Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. , 2000, The European respiratory journal.

[72]  J. V. van Noord,et al.  A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease , 2000 .

[73]  G H Guyatt,et al.  Long-term effects of outpatient rehabilitation of COPD: A randomized trial. , 2000, Chest.

[74]  Chronic bronchitis: the role of viruses. , 2000 .

[75]  P. Bakke,et al.  Impact of patient education and self-management on morbidity in asthmatics and patients with chronic obstructive pulmonary disease. , 2000, Respiratory medicine.

[76]  Calverley Pm.  Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. , 2000 .

[77]  Barnes Pj.  Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. , 2000 .

[78]  A. Ilgazlı,et al.  Inhaled Corticosteroids May Reduce Neutrophilic Inflammation in Patients with Stable Chronic Obstructive Pulmonary Disease , 2000, Respiration.

[79]  P. Lange,et al.  Rehabilitation of patients with chronic obstructive pulmonary disease. Exercise twice a week is not sufficient! , 2000, Respiratory medicine.

[80]  S. Ramsey,et al.  The economic burden of COPD. , 2000, Chest.

[81]  P. Barnes,et al.  The pharmacological properties of tiotropium. , 2000, Chest.

[82]  N. Payne,et al.  Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial , 2000, The Lancet.

[83]  M. Mäkelä,et al.  Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors , 2000, Annals of medicine.

[84]  J R Hughes,et al.  Antidepressants for smoking cessation. , 2007, The Cochrane database of systematic reviews.

[85]  P. Barnes.  Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[86]  A. Chaouat,et al.  A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. , 1999, The European respiratory journal.

[87]  W. Maziak,et al.  Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[88]  M. Sullivan,et al.  Long-term effects of a pulmonary rehabilitation programme in outpatients with chronic obstructive pulmonary disease: a randomized controlled study. , 1999, Scandinavian journal of rehabilitation medicine.

[89]  F. Gigliotti,et al.  Physiological changes during severe airflow obstruction in chronic obstructive pulmonary disease. , 1999, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[90]  D. Postma,et al.  Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .

[91]  P. Burge,et al.  A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[92]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[93]  M. Jordana,et al.  A randomized controlled trial on the effect of inhaled corticosteroids on airways inflammation in adult cigarette smokers. , 1999, Chest.

[94]  P. Dorinsky,et al.  The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. , 1999, Chest.

[95]  S. Yancey,et al.  Efficacy of salmeterol xinafoate in the treatment of COPD. , 1999, Chest.

[96]  R. Zuwallack,et al.  Pulmonary rehabilitation - 1999 , 1999 .

[97]  D. Postma,et al.  Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. , 1999, The New England journal of medicine.

[98]  R. Kotloff,et al.  Lung transplantation. , 2011, American journal of respiratory and critical care medicine.

[99]  W. E. Langbein,et al.  Cycle ergometer and inspiratory muscle training in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[100]  P. Jones,et al.  Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. , 1998, The European respiratory journal.

[101]  B. Beghé,et al.  Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease , 1998, Thorax.

[102]  J. Bourbeau,et al.  Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. , 1998, Thorax.

[103]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[104]  R. Novick,et al.  Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease , 1998, The Lancet.

[105]  K. E. Bendstrup,et al.  Out-patient rehabilitation improves activities of daily living, quality of life and exercise tolerance in chronic obstructive pulmonary disease. , 1997, The European respiratory journal.

[106]  D. Górecka,et al.  Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. , 1997, Thorax.

[107]  David J. Hunter,et al.  Managed care: Disease management , 1997 .

[108]  A. Avenell,et al.  Systematic review of randomised controlled trials , 2018 .

[109]  G. Town,et al.  Evaluation of a self-management plan for chronic obstructive pulmonary disease. , 1997, The European respiratory journal.

[110]  Alan D. Lopez,et al.  Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study , 1997, The Lancet.

[111]  P. Jones,et al.  Quality of life changes in COPD patients treated with salmeterol. , 1997, American journal of respiratory and critical care medicine.

[112]  A. Buist,et al.  Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. , 1997, Chest.

[113]  S. Kivelä,et al.  Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. , 1997, Respiration; international review of thoracic diseases.

[114]  M. Weinberger,et al.  Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. , 1996, The New England journal of medicine.

[115]  M. Tsukino,et al.  Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease. , 1996, Thorax.

[116]  I. Marschner,et al.  Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia. , 1995, American journal of respiratory and critical care medicine.

[117]  P. Jones,et al.  Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. , 1995, American journal of respiratory and critical care medicine.

[118]  A. Ries,et al.  Effects of Pulmonary Rehabilitation on Physiologic and Psychosocial Outcomes in Patients with Chronic Obstructive Pulmonary Disease , 1995, Annals of Internal Medicine.

[119]  G. Guyatt,et al.  Randomized Controlled Trial of Respiratory Rehabilitation , 1995 .

[120]  B. Scherstén,et al.  The impact of health care advice given in primary care on cardiovascular risk , 1995 .

[121]  G. Dinant,et al.  The Efficacy of Influenza Vaccination in Elderly Individuals: A Randomized Double-blind Placebo-Controlled Trial , 1994 .

[122]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[123]  A. Buist,et al.  In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: An 85-day multicenter trial , 1994 .

[124]  A. Buist,et al.  Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. , 1994, American journal of respiratory and critical care medicine.

[125]  T. Meyer,et al.  Noninvasive Positive Pressure Ventilation To Treat Respiratory Failure , 1994, Annals of Internal Medicine.

[126]  D. McDonald,et al.  The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. , 1994, The American journal of physiology.

[127]  D. Postma,et al.  Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. , 1994, The European respiratory journal.

[128]  V. Ninane,et al.  Intrinsic PEEP in patients with chronic obstructive pulmonary disease. Role of expiratory muscles. , 1993, The American review of respiratory disease.

[129]  V. Ninane,et al.  Abdominal muscle use during breathing in patients with chronic airflow obstruction. , 1992, The American review of respiratory disease.

[130]  E. Fletcher,et al.  A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg. , 1992, The American review of respiratory disease.

[131]  E. Bleecker,et al.  The Lung Health Study: Airway Responsiveness to Inhaled Methacholine in Smokers with Mild to Moderate Airflow Limitation , 1992 .

[132]  N. Jones,et al.  Randomised controlled trial of weightlifting exercise in patients with chronic airflow limitation. , 1992, Thorax.

[133]  P. Jones,et al.  Randomised controlled trial of the effectiveness of a respiratory health worker in reducing impairment, disability, and handicap due to chronic airflow limitation. , 1991, Thorax.

[134]  A. Musk,et al.  Upper-limb and lower-limb exercise training in patients with chronic airflow obstruction. , 1990, Chest.

[135]  G. Guyatt,et al.  Measurement of health status. Ascertaining the minimal clinically important difference. , 1989, Controlled clinical trials.

[136]  B. Celli,et al.  Ventilatory muscle dysfunction in patients with bilateral idiopathic diaphragmatic paralysis: reversal by intermittent external negative pressure ventilation. , 1987, The American review of respiratory disease.

[137]  G. Guyatt,et al.  A measure of quality of life for clinical trials in chronic lung disease. , 1987, Thorax.

[138]  J. Moxham,et al.  Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. , 1987, Chest.

[139]  H. D. Short,et al.  Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. , 1987, The American review of respiratory disease.

[140]  N. Anthonisen,et al.  Airways obstruction and the risk for lung cancer. , 1987, Annals of internal medicine.

[141]  A. Guz,et al.  Controlled trial of respiratory health worker visiting patients with chronic respiratory disability. , 1987, British medical journal.

[142]  E. Bleecker,et al.  Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study. , 1986, The American journal of medicine.

[143]  M. Becklake.  Chronic airflow limitation: its relationship to work in dusty occupations. , 1985, Chest.

[144]  F. Khaja,et al.  Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. , 1985, Annals of internal medicine.

[145]  Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. , 1982, JAMA.

[146]  A G Leitch,et al.  Long-term domiciliary oxygen therapy in cor pulmonale complicating chronic bronchitis and emphysema. , 1976, Thorax.